Identification and antimicrobial activity of urinary metabolites of a rifamycin derivative in dog.

1. Three metabolites of the antimicrobial agent 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin (KRM-1648) were isolated from dog urine obtained after administration of a single oral dose. These metabolites of KRM-1648 were identified by mass spectrometry and 1H and 13C-nmr spectrometry. 2. Three metabolites of KRM-1648 were identified as 25-deacetyl KRM-1648, 30-hydroxy KRM-1648 and 25-deacetyl-30-hydroxy KRM-1648. 3. The antimicrobial activities of 25-deacetyl KRM-1648 were comparable with those of the parent compound, whereas 30-hydroxy KRM-1648 was equipotent and 2-8-fold less active than the parent compound against bacteria and mycobacteria, respectively.

[1]  P. Gangadharam,et al.  In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli , 1995, Antimicrobial agents and chemotherapy.

[2]  M. Cynamon,et al.  Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model , 1994, Antimicrobial Agents and Chemotherapy.

[3]  L. Bermudez,et al.  Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages , 1994, Antimicrobial Agents and Chemotherapy.

[4]  L. Bermudez,et al.  Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection , 1994, Antimicrobial Agents and Chemotherapy.

[5]  S. Miyazaki,et al.  In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives , 1994, Antimicrobial Agents and Chemotherapy.

[6]  H. Tomioka,et al.  Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits , 1993, Antimicrobial Agents and Chemotherapy.

[7]  K. Watanabe,et al.  Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives. , 1993, Chemical & pharmaceutical bulletin.

[8]  H. Tomioka,et al.  In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method , 1993, Antimicrobial Agents and Chemotherapy.

[9]  H. Tomioka,et al.  Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice , 1992, Antimicrobial Agents and Chemotherapy.

[10]  H. Tomioka,et al.  In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins , 1991, Antimicrobial Agents and Chemotherapy.

[11]  K. Suzuki,et al.  [In vivo activities of new rifamycin derivatives against mycobacteria]. , 1991, Kekkaku : [Tuberculosis].

[12]  K. Suzuki,et al.  [In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex]. , 1990, Kekkaku : [Tuberculosis].

[13]  C. Inderlied,et al.  Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods , 1987, Antimicrobial Agents and Chemotherapy.

[14]  M. Rybak,et al.  Antimicrobial Susceptibility Tests , 1982, The Medical letter on drugs and therapeutics.